RPCA
ASMB icon

Running Point Capital Advisors’s Assembly Biosciences ASMB Stock Holding History

Running Point Capital Advisors’s Portfolio ASMB Stock Details ASMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-833
Closed -$16K – 216
2022
Q3 		$16K Hold
833
– – 0.01% 185
2022
Q2 		$21K Hold
833
– – 0.01% 183
2022
Q1 		$21K Buy
+833
New +$17.9K 0.01% 184

Other funds holding ASMB

AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Running Point Capital Advisors's ASMB Position: Q4 2022 in Review

Running Point Capital Advisors sold out of Assembly Biosciences (ASMB) in Q4 2022, closing a stake of 833 shares — an estimated $16K sold.

Running Point Capital Advisors first reported a position in ASMB in Q1 2022 and held it in 3 quarters. The position peaked at $21K in Q2 2022. 39 funds tracked by Wall St. Rank hold ASMB as of Q4 2022.

  • Running Point Capital Advisors reported no remaining Assembly Biosciences position as of Q4 2022 after selling out during the quarter.
  • Running Point Capital Advisors sold 833 Assembly Biosciences shares in Q4 2022, an estimated $16K.
  • Running Point Capital Advisors first reported a position in Assembly Biosciences in Q1 2022 and held it in 3 quarters.
  • Running Point Capital Advisors's Assembly Biosciences position peaked at $21K in Q2 2022.
  • 39 funds tracked by Wall St. Rank held Assembly Biosciences as of Q4 2022.

Based on Running Point Capital Advisors's 13F filing for Q4 2022, filed 9 Feb 2023.